Literature DB >> 31908120

Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.

Wilfried Mullens1, Kevin Damman2, Jeffrey M Testani3, Pieter Martens1, Christian Mueller4, Johan Lassus5, W H Wilson Tang6, Hadi Skouri7, Frederik H Verbrugge8, Francesco Orso9, Loreena Hill10, Dilek Ural11, Mitcha Lainscak12, Patrick Rossignol13, Marco Metra14, Alexandre Mebazaa15, Petar Seferovic16, Frank Ruschitzka17, Andrew Coats18.   

Abstract

Appropriate interpretation of changes in markers of kidney function is essential during the treatment of acute and chronic heart failure. Historically, kidney function was primarily assessed by serum creatinine and the calculation of estimated glomerular filtration rate. An increase in serum creatinine, also termed worsening renal function, commonly occurs in patients with heart failure, especially during acute heart failure episodes. Even though worsening renal function is associated with worse outcome on a population level, the interpretation of such changes within the appropriate clinical context helps to correctly assess risk and determine further treatment strategies. Additionally, it is becoming increasingly recognized that assessment of kidney function is more than just glomerular filtration rate alone. As such, a better evaluation of sodium and water handling by the renal tubules allows to determine the efficiency of loop diuretics (loop diuretic response and efficiency). Also, though neurohumoral blockers may induce modest deteriorations in glomerular filtration rate, their use is associated with improved long-term outcome. Therefore, a better understanding of the role of cardio-renal interactions in heart failure in symptom development, disease progression and prognosis is essential. Indeed, perhaps even misinterpretation of kidney function is a leading cause of not attaining decongestion in acute heart failure and insufficient dosing of guideline-directed medical therapy in general. This position paper of the Heart Failure Association Working Group on Cardio-Renal Dysfunction aims at improving insights into the interpretation of renal function assessment in the different heart failure states, with the goal of improving heart failure care.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Acute kidney injury; Biomarkers; Diuretic efficiency; Diuretic response; Glomerular filtration; Guidelines; Heart failure; Kidney function; Outcome; Renal imaging; Tubular function; Worsening of renal function

Mesh:

Substances:

Year:  2020        PMID: 31908120     DOI: 10.1002/ejhf.1697

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  40 in total

Review 1.  Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping.

Authors:  Moemen Eltelbany; Palak Shah; Christopher deFilippi
Journal:  Curr Heart Fail Rep       Date:  2022-10-05

Review 2.  Right Heart Function in Cardiorenal Syndrome.

Authors:  Tilmann Kramer; Paul Brinkkoetter; Stephan Rosenkranz
Journal:  Curr Heart Fail Rep       Date:  2022-09-27

Review 3.  Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome.

Authors:  Zachary L Cox; Veena S Rao; Jeffrey M Testani
Journal:  Kidney360       Date:  2022-03-01

Review 4.  Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.

Authors:  Jason Stencel; Indranee Rajapreyar; Rohan Samson; Thierry Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2022-09-01

5.  The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department.

Authors:  Òscar Miró; Pia Harjola; Xavier Rossello; Víctor Gil; Javier Jacob; Pere Llorens; Francisco Javier Martín-Sánchez; Pablo Herrero; Gemma Martínez-Nadal; Sira Aguiló; María Luisa López-Grima; Marta Fuentes; José María Álvarez Pérez; Esther Rodríguez-Adrada; María Mir; Josep Tost; Lluís Llauger; Frank Ruschitzka; Veli-Pekka Harjola; Wilfried Mullens; Josep Masip; Ovidiu Chioncel; W Frank Peacock; Christian Müller; Alexandre Mebazaa
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2021-06-30

6.  Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure.

Authors:  Veena S Rao; Juan B Ivey-Miranda; Zachary L Cox; Ralph Riello; Matthew Griffin; James Fleming; Richard Soucier; Prasama Sangkachand; Margaret O'Brien; Francine LoRusso; Julie D'Ambrosi; Keith Churchwell; Devin Mahoney; Lavanya Bellumkonda; Jennifer L Asher; Christopher Maulion; Jeffrey M Turner; F Perry Wilson; Sean P Collins; Jeffrey M Testani
Journal:  J Am Coll Cardiol       Date:  2021-02-16       Impact factor: 24.094

7.  Renal sodium avidity, the prevailing renal target in heart failure.

Authors:  Pieter Martens; W H Wilson Tang; Wilfried Mullens
Journal:  Eur Heart J       Date:  2021-11-14       Impact factor: 35.855

8.  Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF.

Authors:  Justas Simonavičius; Micha T Maeder; Casper G M J Eurlings; Arantxa Barandiarán Aizpurua; Jelena Čelutkienė; Jūratė Barysienė; Stefan Toggweiler; Beat A Kaufmann; Hans-Peter Brunner-La Rocca
Journal:  Clin Res Cardiol       Date:  2020-11-20       Impact factor: 5.460

9.  Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease.

Authors:  Yung-Lung Chen; Chi-Ling Hang; Chien-Hao Su; Po-Jui Wu; Huang-Chung Chen; Hsiu-Yu Fang; Yen-Nan Fang; Cheng-I Cheng; Morgan Fu; Shyh-Ming Chen
Journal:  Int J Med Sci       Date:  2021-04-28       Impact factor: 3.738

10.  Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure.

Authors:  Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham
Journal:  JACC Heart Fail       Date:  2021-07-07       Impact factor: 12.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.